Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bgp products gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus nib-104), haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a (victoria lineage)) - injektionssuspension - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus pennino-104) 15 µg, haemagglutininum influenzae b (virus-stamm b/colorado/06/2017-come: reassortant virus (b/veneto/15/2016 nymc bx-69a (victoria lignaggio)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: ovalbuminum max. 0,1 µg, formaldehydum e cetrimidum e polysorbatum 80 e gentamicinum nihil, aqua ad iniectabilia q s. annuncio suspensionem pro 0,5 ml. - aktive immunisierung gegen influenza, ab dem vollendeten 6. lebensmonat - impfstoffe

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

paxvax berna gmbh - haemagglutininum influenzae a (h1n1), neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - injektionssuspension - haemagglutininum influenzae a (h1n1) 15 µg et neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) 15 µg et neuraminidasum inactivatum (virus-stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b), haemagglutininum influenzae b 15 µg et neuraminidasum inactivatum (virus-stamm b/brisbane/60/2008), adjuvans mf59: squalenum, polysorbatum 80, sorbitani trioleas, natrii citras dihydricus, acidum citricum, excipiens: natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesii chloridum hexahydricum, calcii chloridum dihydricum, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza für ältere menschen (65 jahre oder älter), besonders für personen mit erhöhtem risiko für influenza-assoziierte komplikationen - impfstoffe

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-come: reassortant virus pennino-104 ), haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lignaggio)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus nib-104 ) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae di tipo a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b ), haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lignaggio)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b ) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/brisbane/60/2008 (victoria lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bgp products gmbh - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcio chloridum dihydricum, magnesio chloridum hexahydricum, il resto: ovalbuminum max. 0,1 µg, formaldehydum e cetrimidum e polysorbatum 80 e gentamicinum nulla, l'acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

emergent biosolutions berna gmbh - haemagglutininum influenzae di tipo a (h1n1), neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - sospensione iniettabile - haemagglutininum influenzae di tipo a (h1n1) mente.15 µg e neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) mente.15 µg e neuraminidasum inactivatum (virus-stamm a/hong kong/4801/2014 (h3n2)-come: reassortant virus nymc x-263b), haemagglutininum influenzae b mente.15 µg e neuraminidasum inactivatum (virus-stamm b/brisbane/60/2008), natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesio chloridum hexahydricum, calcio chloridum dihydricum, acqua ad iniectabilia q.s. la sospensione 0,5 ml. - immunizzazione attiva contro l'influenza, che abbiano compiuto il 6. mese di vita - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

paxvax berna gmbh - haemagglutininum influenzae di tipo a (h1n1), neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derivato da a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - injektionssuspension - haemagglutininum influenzae a (h1n1) mind.15 µg et neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) mind.15 µg et neuraminidasum inactivatum (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186), haemagglutininum influenzae b mind.15 µg et neuraminidasum inactivatum (virus-stamm b/colorado/06/2017)-like: reassortant virus b/victoria/2/87_b/maryland/15/2016), adjuvans mf59: squalenum, polysorbatum 80, sorbitani trioleas, natrii citras dihydricus, acidum citricum, excipiens: natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesii chloridum hexahydricum, calcii chloridum dihydricum, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza für ältere menschen (65 anni oder älter), besonders für personen mit erhöhtem c'è un rischio per l'influenza-assoziierte komplikationen - impfstoffe

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021), haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) - sospensione iniettabile - haemagglutininum influenzae a (h1n1) (virus stamm a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-227 derived from a/darwin/6/2021) 15 µg, haemagglutininum influenzae b (virus stamm b/austria/1359417/2021-like: reassortant virus bvr-26 derived from b/austria/1359417/2021 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013-like: b/phuket/3073/2013 wild type (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alpha-tocopheroli hydrogenosuccinas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml, residui: ovalbuminum, formaldehydum, natrii desoxycholas, gentamicini sulfas, hydrocortisonum. - immunizzazione attiva contro l'influenza, a partire da 36 mesi - vaccini

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - sospensione iniettabile in siringa pre-riempita - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - immunizzazione attiva contro l'influenza, come già nel 6 ° mese - vaccini